In a study investigating the dynamics of IgA, IgG, and IgM antibody responses in mild and severe SARS-CoV-2 infections, the researchers have found out that IgA antibodies could work as a diagnostic marker, as they start to circulate early after the mild COVID-19-associated symptoms [45]. This evidence concerns the gene CD79A and COVID-19.